

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DOWER. et al.

Application No.: To be assigned

Filing Date: Concurrently herewith

Title: *PEPTIDES AND COMPOUNDS THAT BIND
TO A THROMBOPOIETIN RECEPTOR*

BOX PATENT APPLICATION

Commissioner For Patents

Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Presently submitted independent claims 1 and 16, and dependent claims 3-4 and 17-18 are supported by the specification as originally filed. See e.g. the originally filed claims and the specification at page 5, lines 13-17; page 16, lines 12-16; page 18, lines 5-30; page 50, lines 10-24.

IN THE SPECIFICATION

Page 3, line 18, after "motif" insert —(SEQ ID NO:1)—.

Page 7, line 7, after "amino acids" insert —(SEQ ID NO:2)—;
line 15, after "amino acids" insert —(SEQ ID NO:3)—;
line 25, after "amino acids" insert —(SEQ ID NO:4)—;
line 28, after "amino acids" insert —(SEQ ID NO:5)—;
line 33, after "include:" insert —(SEQ ID NOS 6-13, respectively)—.

Page 8, line 3, after "amino acids" insert —(SEQ ID NO:14)—;
line 14, after "include" insert —(SEQ ID NO:15)—;
line 18, after "amino acids" insert —(SEQ ID NO:16)—.

- Page 9, line 13, after "for" insert --(SEQ ID NO:8)--;
 line 15, after "for" insert --(SEQ ID NO:6)--;
 line 17, after "for" insert --(SEQ ID NO:11)--;
 line 19, after "for" insert --(SEQ ID NO:7)--;
 line 21, after "for" insert --(SEQ ID NO:9)--.
- Page 10, line 30, after "Figure 4B" insert --(SEQ ID NOS 19 & 20, respectively)--;
 line 32, after "Figure 4C" insert --(SEQ ID NOS 223 & 224, respectively)--;
 line 37, after "Figure 5A" insert --(SEQ ID NOS 225 & 226, respectively)--.
- Page 11, line 5, after "Figure 5B" insert --(SEQ ID NOS 227 & 228, respectively)--;
 line 18, after "Figure 6B" insert --(SEQ ID NOS 229 & 230, respectively)--;
 line 21, after "Figure 6C" insert --(SEQ ID NOS 231 & 232, respectively)--.
- Page 24, line 14, after "sequence" insert --(SEQ ID NO:21)--;
 line 17, after "sequence" insert --(SEQ ID NO:22)--;
 line 18, after "library" insert --(SEQ ID NO:23)--.
- Page 25, line 17, after "sequence" insert --(SEQ ID NO:24)--.
- Page 26, line 1, after "Table 1" insert --SEQ ID NOS 25-58, respectively)--.
- Page 27, line 1, after "Table 2" insert --SEQ ID NOS 59-167, respectively)--.
- Page 31, line 24, after "stnicture:" insert --(SEQ ID NO: 15)--;
 line 30, after "Table 3" insert --SEQ ID NOS 6, 7, 8, 9, 168, 11 & 10,
 respectively)--.
- Page 32, line 7, after "acids" insert --(SEQ ID NO:2)--;
 line 15, after "amino acids" insert --(SEQ ID NO:3)--;
 line 25, after "embodiment" insert --(SEQ ID NO:4)--;
 line 28, after "amino acids" insert --(SEQ ID NO:5)--;
 line 33, after "include" insert --(SEQ ID NOS 6-13, respectively)--.

- Page 33, line 4, after "amino acids" insert --(SEQ ID NO:14)--;
line 13, after "include" insert --(SEQ ID NO:15)--;
line 17, after "amino acids" insert --(SEQ ID NO:16)--.
- Page 35, line 6, after "peptide" insert --(SEQ ID NO:6)--;
line 7, after "synthesized" insert --(SEQ ID NO:8)--.
- Page 58, line 5, after "sequences" insert --(SEQ ID NOS 169-171, respectively)--.
- Page 63, Table 4, line 3, after the peptide, insert --(SEQ ID NO:172)--;
line 5, after the peptide, insert --(SEQ ID NO:173)--;
line 7, after the peptide, insert --(SEQ ID NO:174)--;
line 9, after the peptide, insert --(SEQ ID NO:173)--;
line 11, after the peptide, insert --(SEQ ID NO:175)--;
line 13, after the peptide, insert --(SEQ ID NO:176)--.
- Page 64, Table 4, cont., line 2, after the peptide, insert --(SEQ ID NO:177)--;
line 4, after the peptide, insert --(SEQ ID NO:178)--;
line 6, after the peptide; insert --(SEQ ID NO:179)--;
line 8, after the peptide, insert --(SEQ ID NO:180)--;
line 10, after the peptide, insert --(SEQ ID NO:173);
line 12, after the peptide, insert --(SEQ ID NO:181)--.
- Page 65, Table 4, cont., line 2, after the peptide, insert --(SEQ ID NO: 182)--;
line 4, after the peptide, insert --(SEQ ID NO:173)--;
line 6, after the peptide, insert --(SEQ ID NO:173)--;
line 8, after the peptide, insert --(SEQ ID NO:183)--;
line 10, after the peptide, insert --(SEQ ID NO:184)--.
- Page 66, line 5, after "compound" insert --(SEQ ID NO:12)--.
- Page 67, line 1, after "Table 5", after the peptide, insert --(SEQ ID NO:12)--.
- Page 70, line 5, after "compound" insert --(SEQ ID NO:173)--.
- Page 71, line I, after "Table 6", after the peptide, insert --(SEQ ID NO:173)---.

Page 72, line 6, after "monomer" insert --(SEQ ID NO:12)--;
 line 15, after "of" insert --(SEQ ID NO:193)--;
 line 17, after "dimer" insert --(SEQ ID NOS 17 & 18, respectively)--.

Page 73, Table 7, line 4, after the peptide, insert --(SEQ ID NO:173)--;
 line 6, after peptide, insert --(SEQ ID NO: 173)--;
 line 7, after the peptide, insert --(SEQ ID NOS 17)--;
 line 9, after the peptide, insert --(SEQ ID NOS 18)--;
 line 10, after the peptide, insert --(SEQ ID NO:185)--;
 line 12, after the peptide, insert --(SEQ ID NO:185)--;
 line 13, after the peptide, insert --(SEQ ID NO:186)--;
 line 15, after the peptide, insert --(SEQ ID NO:186)--;
 line 16, after the peptide, insert --(SEQ ID NO:187)--;
 line 18, after the peptide, insert --(SEQ ID NO:187)--;
 line 19, after the peptide, insert --(SEQ ID NO:188)--;
 line 21, after the peptide, insert --(SEQ ID NO: 188)--.

Page 74, Table 7, cont., line 3, before the peptide insert --(SEQ ID NO:12)--;
 line 4, before the peptide insert --(SEQ ID NO:173)--;
 line 6, before the peptide insert --(SEQ ID NO:173)--;
 line 7, before the peptide insert --(SEQ ID NO:173)--;
 line 9, before the peptide insert --(SEQ ID NO:173)--;
 line 10, before the peptide insert --(SEQ ID NO:189)--;
 line 12, before the peptide insert --(SEQ ID NO: 189)--;
 line 13, before the peptide insert --(SEQ ID NO:190)--;
 line 15, before the peptide insert --{SEQ ID NO:190)--;
 line 16, before the peptide insert --(SEQ ID NO:190)--;
 line 18, before the peptide insert --(SEQ ID NO:190)--;
 line 19, before the peptide insert --(SEQ ID NO:191)--;
 line 21, before the peptide insert --(SEQ ID NO:191)--;
 line 22, before the peptide insert --(SEQ ID NO:191)--;
 line 24, before the peptide insert --(SEQ ID NO:191)--;
 line 25, before the peptide insert --(SEQ ID NO:192)--;
 line 27, before the peptide insert --(SEQ ID NO:192)--;
 line 28, before the peptide insert --(SEQ ID NO:192)--;
 line 30, before the peptide insert --(SEQ ID NO:192)--.

Page 75, line 1, after "Table 8" insert --(SEQ ID NOS 205-222, respectively)--.

Page 77, Table 9, line 4, after the peptide, insert --(SEQ ID NO:193)--;
line 5, after the peptide, insert --(SEQ ID NO:194)--;
line 6, after the peptide, insert --(SEQ ID NOS 17)--;
line 8, after the peptide, insert --(SEQ ID NOS 18)--;
line 9, after the peptide, insert --(SEQ ID NO:185)--;
line 11, after the peptide, insert --(SEQ ID NO:185)--.

Page 78, Table 10, line 3, after "NH₂" insert --(SEQ ID NOS 17 & 18)--;
line 7, after "NH₂" insert --(SEQ ID NOS 17 & 18)--;
line 10, after "NH₂" insert --(SEQ ID NOS 195 & 196)--;
line 13, after "NH₂" insert --(SEQ ID NOS 197 & 198)--;
line 16, after "NH₂" insert --(SEQ ID NOS 199 & 200)--;
line 19, after "NH₂" insert --(SEQ ID NOS 199 & 200)--;
line 22, after "NH₂" insert --(SEQ ID NOS 201 & 202)--;
line 25, after "NH₂" insert --(SEQ ID NOS 203 & 204)--;
line 28, after "NH₂" insert --(SEQ ID NOS 203 & 204)--.

Page 79, line 5, after "compound" insert --(SEQ ID NO:12)--.

Page 85, at the end of the specification, before the claims, insert the printed Sequence Listing submitted concurrently herewith.

REMARKS

Applicants submits this amendment to insert required references to the sequence listing into the specification and to provide support of claims 1-18.

Respectfully submitted,

W. E. Bennett

Virginia C. Bennett
Attorney of Record
Registration No. 37,092

Date: 27 Feb. 02
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Telephone: (919) 483-1012
Facsimile: (919) 483-7988